The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

JULY 1, 2024

Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for PYZCHIVA (ustekinumab-ttwe) subcutaneous injection and intravenous infusion as a biosimilar to Stelara (ustekinumab).

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

APRIL 4, 2024

Today, one dose of Bimzelx in moderate-to-severe plaque psoriasis is administered as two 1mL injections. Approval of the 2mL device presentations would mean that patients would have an alternative one-injection regimen option,” Caeymaex says. In addition, improvements increased for patients in these studies over 48 weeks. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

Aesthetics Advisor

JULY 4, 2024

In recent years, the allure of IV drip therapy has surged, captivating both health enthusiasts and celebrities alike. In an exploration of the scientific realms of IV drip therapy, we talked to Dr. Anant Vinjamoori, MD, Chief Medical Officer of Modern Age and Harvard-trained longevity expert. What is IV drip therapy?

Therapy 36

Therapy Vitamin C Injections Medical 36

US Dermatologt Partners

JANUARY 13, 2025

Heres why you should schedule a dermatologic session for professional acne treatment : Safety and comfort dermatologists are trained to perform extractions under sterile conditions, which drastically reduces the risk for infection and improves chances for acne scar prevention.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

AAAMS

MAY 9, 2024

This led to the development of specialized aesthetic nurse training programs that teach nurses how to administer injectables, perform laser treatments, and provide skincare services. Nurses were first taught the importance of maintaining a clean and sterile environment, with safety being the top priority.

Training 52

Training Technology Ethics Injections 52

AAAMS

AUGUST 4, 2023

Through the skillful administration of precise injections into targeted head and neck muscles, Botox for headaches obstructs the release of specific pain-transmitting chemicals. While some patients may be free of migraines through Botox alone, others may need additional treatments or therapies. Does Botox Work for Migraines?

Injections 52

Injections Surgery Medical Training 52

AAAMS

AUGUST 4, 2023

Through the skillful administration of precise injections into targeted head and neck muscles, Botox for headaches obstructs the release of specific pain-transmitting chemicals. While some patients may be free of migraines through Botox alone, others may need additional treatments or therapies. Does Botox Work for Migraines?

Injections 52

Injections Surgery Medical Training 52

The Dermatology Digest

OCTOBER 21, 2024

Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or off-label biologics, underscoring the growing unmet need for novel therapeutic options to treat this condition.

Treatments 41

Treatments Injections Therapy Management 41

The Dermatology Digest

JUNE 28, 2021

First approved long-acting injectable for HIV by Bob Kronemyer The first injectable and complete regimen for HIV-infected adults was approved in January by the Food and Drug Administration (FDA). of patients in the injection group and only 1.0% At week 48, for the primary endpoint, only 1.6% Conversely, 92.5% to 0.7).

Injections 36

Injections Therapy Treatments Office 36

The Dermatology Digest

DECEMBER 14, 2023

The study included 30 patients with ≥3% BSA who have been on stable biologic therapy for at least 26 weeks. Patients returned at week 16 to assess safety and evaluate maintenance response. ” Moreover, Vtama cream was well tolerated, with no new safety signals when used in combination with injectable biologics.

Injections 36

Injections Safety Office Therapy 36

The Dermatology Digest

APRIL 17, 2024

The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CIndU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. The study enrolled 40 healthy adult participants into three single-ascending dose (SAD) and two multiple-ascending dose (MAD) cohorts.

Injections 36

Injections Safety Clinic Sustainability 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 13, 2024

The CHMP has recommended nemolizumabs approval for subcutaneous use for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate to severe prurigo nodularis who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Marketing Therapy 36

The Dermatology Digest

SEPTEMBER 9, 2024

It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume. The toxin is made with and Revances’s proprietary Peptide Exchange Technology (PXT).

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

OCTOBER 10, 2024

The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of KT-621 compared to placebo. Dupilumab, an injectable monoclonal antibody that blocks IL-4/IL-13 signaling, is an approved therapy for multiple allergic and atopic diseases.

Clinic 36

Clinic Injections Dermatitis Safety 36

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. “We are encouraged by the study findings published in NEJM , including consistency across clinician and patient-reported outcomes and objective biomarkers.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

AUGUST 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

Spa Executive

JUNE 28, 2024

Wellness retreats continue to proliferate across the country, offering travelers opportunities to rejuvenate through practices like yoga, meditation, spa treatments and alternative therapies. These therapies are offered in dedicated sound therapy spaces within the spa or wellness facility, or even integrated into the hydrotherapy area.

Sustainability 52

Sustainability Therapy Technology Medical 52

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

Aesthetics Advisor

JUNE 16, 2024

As with so many skin-care trends that have come before, this one is rooted in medicine — in this case, regenerative medicine, which is centered on developing and applying therapies to help the body heal itself. Nanofat injections , a newer phenomenon, harvest a mix of cells, including stem cells, from a person’s own body fat.

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

AAAMS

APRIL 21, 2024

During the procedure, a solution containing saline, epinephrine, and lidocaine is injected into the fatty tissue, which makes it firm and swollen. To ensure patient safety and achieve optimal results, healthcare professionals must be well-versed in the fundamental concepts of body contouring.

Training 52

Training Technology Medical Safety 52

Fairlawn Aesthetic MD

MARCH 14, 2024

Part of this personalized approach includes being upfront about who will most benefit from semaglutide/NAD+ therapy – and, importantly, who may not. Pregnancy or Nursing: The safety of semaglutide for pregnant women and nursing mothers is still under study, so we prefer to err on the side of caution. And the best part?

Injections 36

Injections Management Medical Office 36

Aesthetics Advisor

AUGUST 25, 2023

Unlike these nutrients, it’s absent from the human body, only making its way in through medical injections tailored for diagnostic purposes. The first three I saw, including a fellow doctor, described feeling sick post the GBCA injection at my center. These symptoms can manifest immediately or within a month of the GBCA injection.

Injections 36

Injections Medical Safety Tools 36

US Dermatologt Partners

JANUARY 24, 2024

Multiple sclerosis (MS) –People with MS, especially those who receive disease-modifying therapies, are significantly more likely to develop psoriasis, according to research presented at the 2021 Consortium of Multiple Sclerosis Centers. Symptoms include abdominal cramping, changes in bowel movements, and blood in the stool.

Management 36

Management Skin Health Medical Dermatology 36

Aesthetics Advisor

MARCH 10, 2024

Steroids are the first-line therapy, but then there are immunosuppressants as well, with more in the drug pipeline. Previously, I talked about the safety and efficacy of other, more natural treatments. Previously, I talked about the safety and efficacy of other, more natural treatments. But what about diet? But what about diet?

Eczema 36

Eczema Diet Dermatitis Document 36

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy. Platelet-Rich Plasma Therapy for Hair Growth: A Systematic Review. Microblading: Safety and Efficacy in Eyebrow Enhancement.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

Aesthetics Advisor

AUGUST 18, 2023

Key Points: A few studies show that NAD+ IV therapy can alleviate alcohol and drug addiction, as well as Parkinson’s disease, but no studies have examined its effects on aging. Oral administration of NAD+ boosting therapy is safer, more cost effective, and more consistently dosed than intravenous administartion.

Therapy 36

Therapy Injections Safety Clinic 36

Aesthetics Advisor

AUGUST 19, 2023

Nevertheless, PRP and exosome-related therapies are not yet established as standard treatments, given their relatively recent emergence. Because the human body is specially equipped to heal itself, and regenerative therapies tap into this powerful ability. It is a substance that’s thought to promote healing when injected.

Therapy 36

Therapy Injections Medical Treatments 36

Aesthetics Advisor

AUGUST 15, 2023

The research included injecting different types of cancers into different mice body parts. Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement. Fenbendazole has been reported to have a very low degree of toxicity and a high degree of safety in animal experiments.

Therapy 69

Therapy Medical Safety Diet 69

The Dermatology Digest

MAY 15, 2021

So we’re looking for a way to sensitize or in some cases re-sensitize this disease to immune checkpoint inhibitor therapy.” Patients underwent intratumoral (IT) cavrotolimod injections once weekly for 8 weeks, then once every 3 weeks; pembrolizumab dosing occurred every 3 weeks, starting at week 3.

Injections 36

Injections Clinic Safety Therapy 36

The Dermatology Digest

MAY 23, 2021

So we’re looking for a way to sensitize or in some cases re-sensitize this disease to immune checkpoint inhibitor therapy.” Patients underwent intratumoral (IT) cavrotolimod injections once weekly for 8 weeks, then once every 3 weeks; pembrolizumab dosing occurred every 3 weeks, starting at week 3.

Injections 36

Injections Clinic Safety Therapy 36

The Dermatology Digest

MAY 8, 2024

If approved by the FDA, the subcutaneous administration of nivolumab would provide patients and their physicians with a new option that delivers the same well-known benefits as IV Opdivo but with the improved convenience of an injection administered in 3-to-5 minutes rather than a 30-to-60-minute infusion.”

Safety 36

Safety Therapy Injections Dermatology 36

The Dermatology Digest

AUGUST 14, 2024

Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study. VP315 has the potential to change the way dermatologists treat basal cell skin cancer. It’s very, very exciting data.”

Pharmaceutical 36

Pharmaceutical Safety Clinic Dermatology 36